Press releases // 15 March 2019
IntegraGen to present at 6th annual Portzamparc MidCap Conference – April 10, 2019
Come and meet us at the #ConfMidCap2019 @Portzamparc, April 10th!
Press releases // 05 March 2019
IntegraGen and Advanced Biological Laboratories sign global licensing agreement for the commercialization of miRpredX test
IntegraGen and Advanced Biological Laboratories (ABL) have announced the signing of a non-exclusive global licensing agreement enabling ABL to distribute miRpredX™, IntegraGen’s proprietary IVD CE marked diagnostic test that enables clinicians to identify metastatic colorectal cancer patients who have a higher likelihood of response to anti-EGFR therapy.
Press releases // 09 January 2019
IntegraGen Reports Revenue of €6.9 million for 2018 (+11%) and Cash Position of €4.0 million
IntegraGen announced today its unaudited annual sales revenue for 2018.
Sales revenue of €6.9 million (+11%) Very strong increase (+29%) in sequencing services for the R&D segment Strong reduction in cash consumption. Cash position of €4.0 million as of December 31, 2018 Commercial launch of SIRIUS and MERCURY online genomic data (…) »Press releases // 12 November 2018
IntegraGen Announces Collaboration with Google Cloud to Offer Large Scale Genomic Analysis Tools for Clinicians and Medical Researchers
IntegraGen has announced it is collaborating with Google Cloud for the implementation of IntegraGen’s advanced genomic analysis tools, SIRIUS™ and MERCURY™ into the Google Cloud Platform. This partnership will enable widespread online availability, rapid data transfer and enhanced data security to clinicians and researchers utilizing these analytical tools.
(…) »Press releases // 20 September 2018
IntegraGen Reports Financial Results for 1st Half of 2018
IntegraGen has announced today its financial results for the first half of semester 2018 with the accounts having been examined by the company’s Board of Directors on September 20, 2018.
Sales revenue: 3.7 M€, +17% vs. H1 2017 Significant growth in genomics services Operating profit: -0.5 M€, + 57% vs. (…) »Press releases // 04 September 2018
IntegraGen Announces Publication of miR-31-3p Data in Clinical Cancer Research
IntegraGen announces the publication of the results of a definitive study reporting on the analysis of the expression of miR-31-3p in tumors from 370 RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients enrolled in the FIRE-3 clinical trial (AIO KRK-0306). The paper, entitled “Validation of miR-31-3p Expression Level to Predict (…) »
Press releases // 31 July 2018
The SeqOIA Cooperative Health Group selects IntegraGen as the operator of its sequencing platform as part of the France Genomic Medicine 2025 Plan
IntegraGen has announced that it has been selected by the Sequencing Omics Information Analysis (SeqOIA) Cooperative Health Group (GCS) for the operation of its high throughput sequencing platform. The SeqOIA GCS, which includes the Assistance Publique- Hôpitaux de Paris, the Institut Curie and the Gustave Roussy Cancer Center, (…) »
